ArticleMolecular psychiatry2026
Transcriptome-informed brain cartography of polygenic risk and association with brain structure in major psychiatric disorders.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric disorders are complex, polygenic conditions characterized by patterned structural brain alterations. Whether these changes reflect transcriptional dysregulation driven by genetic risk remains unclear. We introduce a novel imaging-transcriptomics framework that integrates transcriptome-wide association studies (TWAS) with brain transcriptomic atlases to predict macroscale structural brain abnormalities across seven disorders: attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), anorexia nervosa (AN), bipolar disorder (BD), major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and schizophrenia (SCZ). We generated disorder-related Gene Expression-based Disorder Associated Risk (GEDAR) maps and assessed their spatial correlation with observed brain alterations thereby establishing a structured approach to map polygenic transcriptional risk onto macroscale brain phenotypes. We found significant transcriptomic-anatomical correlations in MDD (cortical and subcortical), SCZ (subcortical), and ADHD (subcortical), indicating that regional transcriptional vulnerability might contribute to varying extents to the anatomical expression of genetic risk in these disorders. Pathway enrichment analysis on genetically predicted differentially expressed genes for those disorders where we found spatial correlations between GEDAR maps and observed structural changes revealed immune-related processes as dominant in MDD and SCZ, and neurodevelopmental pathways in ADHD. Importantly, spatial transcriptomic-anatomical alignment did not scale with between-disorder differences in heritability, pointing instead toward additional influences like developmental timing or environmental interactions. These findings underscore the potential and limitations of imaging transcriptomics as a framework for bridging the gap between genetic architecture and systems-level brain changes in psychiatric disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.